Melanoma Research Review, Issue 5

In this Issue:

COMBI-v trial: health-related quality of life
Acute skin reaction suggestive of pembrolizumab-induced radiosensitisation
Advanced BRAF V600-mutant melanoma and BRAF inhibitor rechallenge
Effect of time to sentinel-node biopsy on the prognosis of cutaneous melanoma
Regression in primary melanoma and sentinel lymph node status
Immune-related adverse events in patients with melanoma treated with ipilimumab
Nicotinamide for skin-cancer chemoprevention
Isolated limb perfusion in melanoma patients with recurrent in-transit metastases
Incidence of and risk factors associated with multiple primary melanomas
Cutaneous toxic effects of BRAF inhibitor monotherapy and CombiDT therapy

Please login below to download this issue (PDF)

Subscribe